Legend Biotech Corporation
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| LEGN | 2171.HK | LYEL | 2126.HK | CGEM | 2616.HK | |
|---|---|---|---|---|---|---|
| Market cap | 4.43B | 6.48B | 378.11M | 1.11B | 767.61M | 8.98B |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | 21.7 | 96.2 | -2.4 | -3.0 | -5.1 | 137.0 |
| Price/book | 3.6 | 5.0 | 1.5 | 2.0 | 2.5 | 5.9 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −29.66% | −29.62% | −34.89% | −31.72% | +69.93% | −7.84% |
| Today | +6.01% | +3.36% | +43.27% | +7.91% | −20.70% | +4.16% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All LEGN news ›Legend Biotech Announces Chief Executive Officer Transition
SOMERSET, N.J. --(BUSINESS WIRE)--Aug. 2, 2020-- Legend Biotech Corporation (NASDAQ: LEGN) ( Legend Biotech ), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology…
Legend Biotech Announces Seven Presentations on CARVYKTI and Pipeline at ASH 2026
Kalkine Media On November 4, 2026, Legend Biotech Corporation submitted a Form 6-K revealing seven presentations scheduled for the 68th American Society of Hematology Annual Meeting, with five specifically highlighting
Legend Biotech to Showcase CARVYKTI® Leadership and Next-Generation Cell Therapy Innovation at ASH 2026
November 04, 2026 09:00 ET | Source: Legend Biotech USA Inc. Legend Biotech USA Inc. The CARVYKTI presentations include new analyses from the CARTITUDE-4 study providing additional insights into outcomes in earlier-line treatment, as well…
Forbes China names OPH Health founder Leona Tong top leader
OPH Health founder Leona Tong earned selection to the 2026 Forbes China 100 list, recognizing her Singapore digital health enterprise for deploying clinical artificial intelligence tools. Forbes China names OPH Health founder Leona Tong…
Legend Biotech Announces U.S. FDA Clearance of IND Application for LB2501, an Investigational CD19/CD20 In Vivo CAR-T Therapy
LB2501 is an off-the-shelf in vivo CAR-T therapy designed to generate dual-targeting CD19/CD20 CAR-T cells directly within the patient after a single infusion, making it the first known dual-targeting in vivo CAR-T therapy to receive FDA…
More from 4 other outlets
- markets.businessinsider.com Legend Biotech announces FDA clearance of LB2501 IND application
- RTTNews Legend Biotech Wins FDA Clearance For In Vivo CAR-T Therapy LB2501; Stock Up
- MarketScreener Legend Biotech Corporation Announces U.S. FDA Clearance of IND Application for LB2501, Investigational CD19/CD20 in Vivo CAR-T Therapy
- Oncodaily - Oncology News Legend Biotech Receives FDA IND Clearance for LB2501, a CD19/CD20 In Vivo CAR-T Therapy
Legend Biotech Corp ADR LEGN
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric…
Legend Biotech (NASDAQ:LEGN) Stock Price Crosses Above 50 Day Moving Average – Should You Sell?
Posted by Kim Johansen on Oct 27th, 2026 Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN – Get Free Report) shares passed above its 50 day moving average during trading on Monday. The stock has a 50 day moving average of $19.52 and…
Legend Biotech: Carvykti Makes Billions, But The Profits Are Elusive
Legend Biotech's Q2 shows CARVYKTI sales hitting $710M and improving operating leverage. Find out why LEGN stock is a buy. - CARVYKTI's quarterly sales reached $710 million, but Legend's high expenses have kept recurring profitability low.…
Legend Biotech price target lowered to $56 from $58 at RBC Capital
RBC Capital analyst Leonid Timashev lowered the firm’s price target on Legend Biotech (LEGN) to $56 from $58 and keeps an Outperform rating on t... Legend Biotech price target lowered to $56 from $58 at RBC Capital RBC Capital analyst…
Legend Biotech price target lowered to $68 from $74 at Barclays
Barclays lowered the firm’s price target on Legend Biotech (LEGN) to $68 from $74 and keeps an Overweight rating on the shares. The firm adjuste... Legend Biotech price target lowered to $68 from $74 at Barclays Barclays lowered the firm’s…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com9
- markets.businessinsider.com6
- investors.legendbiotech.com2
- globenewswire.com1
- morningstar.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 24 articles, not a forecast.